STOCK TITAN

Sig Kirk Joins Assertio Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Assertio Holdings, Inc. appoints Sigurd Kirk, a seasoned pharmaceutical executive, to its board of directors, bringing extensive experience in business development and financial management. Kirk's background includes executive roles at Allergan plc and Barr Pharmaceuticals, enhancing Assertio's strategic growth initiatives.
Positive
  • None.
Negative
  • None.

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors. He will serve on the Audit and Compensation committees.

Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products. His previous experience includes 11 years at Allergan plc, which was acquired by AbbVie, Inc., as Executive Vice President, Corporate Business Development, where he led more than 75 deals. Prior to that, he served in multiple senior leadership roles at Barr Pharmaceuticals, now Teva Pharmaceuticals, Inc., including Global Controller and Chief Accounting Officer. Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification. He holds a Bachelor of Business Administration degree from Pace University.

“Sig’s extensive strategic business development, financial management and diligence background are an excellent resource for a growth-oriented business like Assertio as we continue to seek exciting commercial assets where our innovative digital non-personal promotion platform and efficient oncology field sales force can deliver incremental performance,” said Heather Mason, interim Chief Executive Officer. “Both Sig’s appointment and the addition of Sravan Emany last fall demonstrate our ongoing commitment to aligning our board expertise with our evolving business strategies.”

About Assertio

Assertio is a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.

Forward Looking Statements

Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio, including risks related to our ability to realize the benefits from our operating model, successfully integrate new assets, explore new business development initiatives, and successfully recruit a successor CEO on a timely basis. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” “believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio, including the risks described in Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) and in other filings Assertio makes with the SEC from time to time. Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.

Investor Contact

Matt Kreps, Managing Director
Darrow Associates
M: 214-597-8200
mkreps@darrowir.com


FAQ

Who was appointed to Assertio Holdings, Inc.'s board of directors?

Sigurd Kirk was appointed to Assertio Holdings, Inc.'s board of directors.

What is Sigurd Kirk's professional background?

Sigurd Kirk has more than 20 years of pharmaceutical experience in branded biopharmaceutical, medical device, and generic products. He previously worked at Allergan plc and Barr Pharmaceuticals.

What committees will Sigurd Kirk serve on?

Sigurd Kirk will serve on the Audit and Compensation committees of Assertio Holdings, Inc.

What is Heather Mason's role at Assertio Holdings, Inc.?

Heather Mason is the interim Chief Executive Officer of Assertio Holdings, Inc.

What is the ticker symbol for Assertio Holdings, Inc.?

The ticker symbol for Assertio Holdings, Inc. is ASRT.

Assertio Holdings, Inc.

NASDAQ:ASRT

ASRT Rankings

ASRT Latest News

ASRT Stock Data

81.18M
92.85M
2.62%
31.94%
6.55%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
LAKE FOREST